LabCorp Announces Definitive Agreement to Acquire Tandem Labs, Inc.

BURLINGTON, N.C.--(BUSINESS WIRE)--Jan. 24, 2008--Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) and Tandem Labs, a leading bioanalytical and immunoanalytical contract research organization (CRO) supporting pharmaceutical and biotechnology companies with their discovery,

LabCorp(R) Announces the Availability of Affymetrix-Based Whole Genome Microarrays

BURLINGTON, N.C., Jan 22, 2008 (BUSINESS WIRE) -- Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) is pleased to announce the availability of an ultra high-density microarray, Affymetrix based technology (Whole-Genome Sampling Analysis).

LabCorp Licenses Technology for Early Detection of Lung Cancer from Duke University

BURLINGTON, N.C.--(BUSINESS WIRE)--Jan. 17, 2008--Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE:LH) today announced that it has entered into an exclusive license agreement with Duke University Medical Center (Duke) to commercialize Duke's new blood-based assay for early detection

LabCorp is Scheduled to Present at the Merrill Lynch Health Services Investor Conference

BURLINGTON, N.C.--(BUSINESS WIRE)--Nov. 26, 2007--Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE:LH) today announced that William B. (Brad) Hayes, Executive Vice President and Chief Financial Officer, and Bradford T. Smith, Executive Vice President, Corporate Affairs, are

LabCorp Announces $500 Million Stock Repurchase Program

BURLINGTON, N.C.--(BUSINESS WIRE)--Nov. 5, 2007--Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) today announced that its Board of Directors has authorized a new stock repurchase program under which LabCorp may purchase up to an aggregate of $500,000,000 of its Common Stock

LabCorp(R) Launches Integrated and Sequential Prenatal Screening Technology for Down Syndrome

More Sensitive Technology Improves Assessment of Down Syndrome Risk BURLINGTON, N.C.--(BUSINESS WIRE)--Oct. 25, 2007--Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH), an industry leader in prenatal clinical laboratory testing, announced that it now offers Integrated screening

Laboratory Corporation of America(R) Holdings Announces 2007 Third Quarter Results

Third Quarter Net Sales Growth of 12.2% Drives EPS Growth Before Charges of 27.4% BURLINGTON, N.C.--(BUSINESS WIRE)--Oct. 25, 2007--Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) today announced results for the quarter and nine months ended September 30, 2007.

Medco, LabCorp Strike Strategic Agreement for Research on Personalized Medicine and Pharmacogenomics

Collaboration to Explore Clinical Uses of Personal Genetics and Tamoxifen FRANKLIN LAKES, N.J. & BURLINGTON, N.C.--(BUSINESS WIRE)--Oct. 22, 2007--Medco Health Solutions Inc. (NYSE:MHS) and Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE:LH) announced a strategic research

Conversion Right Triggered for LabCorp's Liquid Yield Option(TM) Notes Due 2021 and Zero Coupon Convertible Subordinated Notes Due 2021

BURLINGTON, N.C.--(BUSINESS WIRE)--Oct. 3, 2007--Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE:LH) announced today that its zero coupon subordinated Liquid Yield Option(TM) Notes due 2021 (LYONs) and Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be

LabCorp's Liquid Yield Option(TM) Notes Due 2021 and Zero Coupon Convertible Subordinated Notes Due 2021 to Accrue Contingent Interest

BURLINGTON, N.C.--(BUSINESS WIRE)--Sept. 12, 2007--Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) announced today that for the period of September 12, 2007 to March 11, 2008, its zero coupon subordinated Liquid Yield Option(TM) Notes due 2021 (LYONs) and Zero Coupon